Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | Director | May 28, 2020 | June 01, 2020 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | May 24, 2024 | May 29, 2024 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 15, 2026 | May 16, 2026 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | June 17, 2026 | June 18, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERCEPT PHARMACEUTICALS, INC.
Report date May 28, 2020 · Filed June 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,060 |
Reported balance
After 2020-05-28 transaction · row 1
1 source rowRow 1 · 2020-05-28 · Grant · Acquired 1,595 · Balance 8,060 F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 · Expires 2030-05-28 | Direct | 2,966 |
Reported balance
After 2020-05-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-28 · Grant · Acquired 2,966 · Balance 2,966 F2: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders.
F2: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders.
Nuvation Bio Inc.
Report date May 24, 2024 · Filed May 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 659,947 |
Ending reported balance
After 2024-05-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-24 · Exercise / conversion · Acquired 293,203 · Balance 293,203 Row 2 · 2024-05-24 · Exercise / conversion · Acquired 366,744 · Balance 659,947 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-07-21 | Direct | 19,547 |
Reported balance
After 2024-05-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-24 · Exercise / conversion · Disposed 293,203 · Balance 19,547 F1: Option vests in 48 equal monthly installments from July 22, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2033-05-14 | Direct | 0 |
Reported balance
After 2024-05-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-24 · Exercise / conversion · Disposed 366,744 · Balance 0 F2: Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in 48 equal monthly installments from July 22, 2020.
F2: Option is fully vested and exercisable.
PROTHENA CORP PUBLIC LTD CO
Report date May 15, 2026 · Filed May 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.76 · Expires 2036-05-15 | Direct | 27,000 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
Structure Therapeutics Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16 | Direct | 39,453 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,441 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 40,441 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Acquired 1,106 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2026-02-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 35,552 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.25 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 2,454 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 2,905 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 4,750 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 0 |
Reported balance
After 2023-12-14 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-12-14 · Disposition to issuer · Disposed 10,725 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,305 | $165.62 | $547,374.10 |
DisclosureSEC source: 0001203311-20-000028 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,958 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $164.88 to $165.86. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 20:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001203311-20-000002 · edgardoc.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2020-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 20:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 17,500 | $12.76 | $223,300.00 |
DisclosureSEC source: 0001203311-20-000002 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,174 | $0.00 Strike: $82.25 | $0.00 |
DisclosureSEC source: 0001144204-19-031952 · tv524013_4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires 2029-06-20 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031952 · tv524013_4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,465 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.74 | $0.00 |
DisclosureSEC source: 0001209191-19-036825 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-11 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036825 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document |
| May 20, 2019 Filed May 22, 2019 21:33 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,038 | $0.00 Strike: $64.38 | $0.00 |
DisclosureSEC source: 0000899243-19-014427 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,038 Underlying: Common Stock · 7,038 shares Expires 2029-05-20 F3 · derivative.exercise_date: These options shall vest in full on May 20, 2020. Read SEC document |
| May 20, 2019 Filed May 22, 2019 21:33 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 2,963 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014427 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,763 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 20, 2020. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,748 | $0.00 Strike: $85.12 | $0.00 |
DisclosureSEC source: 0001144204-18-035419 · tv496986_4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,748 Underlying: Common Stock · 2,748 shares Expires 2028-06-20 F2 · derivative.exercise_date: All of the shares subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-035419 · tv496986_4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,895 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 21:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $80.69 | $0.00 |
DisclosureSEC source: 0001209191-18-038831 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-19 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 21:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038831 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document |
| May 18, 2018 Filed May 22, 2018 20:13 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,260 | $0.00 Strike: $56.77 | $0.00 |
DisclosureSEC source: 0001203311-18-000039 · edgardoc.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 Underlying: Common Stock · 9,260 shares Expires 2028-05-18 F3 · derivative.exercise_date: The option shall vest in full on May 18, 2019. Read SEC document |
| May 18, 2018 Filed May 22, 2018 20:13 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-18-000039 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,800 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · deemedExecutionDate: Restricted stock units shall vest in full on May 18, 2019. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:43 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,905 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-030133 · doc4.xml · derivative · entry 4 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,905 shares Expires 2028-03-13 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:43 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,454 | $0.00 Strike: $69.25 | $0.00 |
DisclosureSEC source: 0001209191-18-030133 · doc4.xml · derivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,454 shares Expires 2027-05-30 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:43 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,552 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030133 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,552 shares Expires 2026-02-10 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:43 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerCommon Stock | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030133 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2 · shares: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. Read SEC document |
| March 13, 2018 Filed Mar 30, 2018 17:50 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantStock Option (Right to Buy) · Derivative | 2,905 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-022239 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,905 Underlying: Common Stock · 2,905 shares Expires 2028-03-13 F2 · derivative.exercise_date: This option shall vest and become exercisable on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. Read SEC document |
| March 13, 2018 Filed Mar 30, 2018 17:50 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantCommon Stock | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-022239 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. F1 · price: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:21 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.08 | $0.00 |
DisclosureSEC source: 0001203311-18-000010 · edgardoc.xml · derivative · entry 4 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested in full on May 15, 2009. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:21 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,881 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001203311-18-000010 · edgardoc.xml · derivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,881 shares Expires 2019-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested in full on May 14, 2010. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:21 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 6,881 | $8.38 | $57,662.78 |
DisclosureSEC source: 0001203311-18-000010 · edgardoc.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:21 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 10,000 | $10.08 | $100,800.00 |
DisclosureSEC source: 0001203311-18-000010 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 602 | $123.93 | $74,603.69 |
DisclosureSEC source: 0001144204-17-040072 · v472267_form4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,108 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 217 | $126.76 | $27,506.92 |
DisclosureSEC source: 0001144204-17-037729 · v471224_form4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,710 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,036 | $0.00 Strike: $122.01 | $0.00 |
DisclosureSEC source: 0001144204-17-035034 · v470075_form4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Underlying: Common Stock · 2,036 shares Expires 2027-06-27 F1 · derivative.exercise_date: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-035034 · v470075_form4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,927 F1 · shares: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 23:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001209191-17-041478 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-06-22 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 23:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041478 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 18:05 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantStock Option (Right to Buy) · Derivative | 2,454 | $0.00 Strike: $69.25 | $0.00 |
DisclosureSEC source: 0001209191-17-036890 · doc4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454 Underlying: Common Stock · 2,454 shares Expires 2027-05-30 F1 · derivative.exercise_date: The option shall vest and become exercisable (i) in twelve equal monthly installments beginning on June 30, 2017, or (ii) on the date of the Issuer's next annual stockholder meeting, whichever comes first, in each case subject to the Reporting Person's Continuous Service (as that term is defined in the Issuer's 2016 Equity Incentive Plan) through each such date. Read SEC document |
| May 19, 2017 Filed May 23, 2017 19:24 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,260 | $0.00 Strike: $66.60 | $0.00 |
DisclosureSEC source: 0001203311-17-000026 · edgardoc.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 Underlying: Common Stock · 9,260 shares Expires 2027-05-18 F3 · derivative.exercise_date: The option shall vest in full on May 18, 2018. Read SEC document |
| May 19, 2017 Filed May 23, 2017 19:24 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-17-000026 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,219 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Restricted stock units shall vest in full on May 18, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.